SG Americas Securities LLC purchased a new position in Heska Corp (NASDAQ:HSKA) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,836 shares of the medical research company’s stock, valued at approximately $191,000.
Several other institutional investors also recently bought and sold shares of the company. State Board of Administration of Florida Retirement System boosted its holdings in shares of Heska by 23.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 3,581 shares of the medical research company’s stock worth $372,000 after acquiring an additional 670 shares during the period. Rhumbline Advisers boosted its holdings in shares of Heska by 6.3% in the second quarter. Rhumbline Advisers now owns 16,376 shares of the medical research company’s stock worth $1,700,000 after acquiring an additional 977 shares during the period. Alps Advisors Inc. bought a new position in shares of Heska in the second quarter worth $388,000. Piedmont Investment Advisors LLC bought a new position in shares of Heska in the second quarter worth $162,000. Finally, Fred Alger Management Inc. boosted its holdings in shares of Heska by 157.4% in the second quarter. Fred Alger Management Inc. now owns 277,687 shares of the medical research company’s stock worth $28,821,000 after acquiring an additional 169,804 shares during the period. 89.15% of the stock is owned by hedge funds and other institutional investors.
In related news, EVP Steven M. Eyl sold 33,351 shares of Heska stock in a transaction on Monday, August 13th. The stock was sold at an average price of $98.49, for a total transaction of $3,284,739.99. Following the completion of the sale, the executive vice president now owns 15,401 shares of the company’s stock, valued at $1,516,844.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Jason A. Napolitano sold 1,200 shares of Heska stock in a transaction on Monday, July 9th. The shares were sold at an average price of $110.00, for a total value of $132,000.00. The disclosure for this sale can be found here. Insiders have sold 55,278 shares of company stock valued at $5,561,060 in the last three months. 14.70% of the stock is owned by corporate insiders.
NASDAQ:HSKA opened at $109.97 on Friday. The firm has a market cap of $818.46 million, a P/E ratio of 53.13 and a beta of 0.52. Heska Corp has a 52-week low of $56.59 and a 52-week high of $112.25.
Heska (NASDAQ:HSKA) last posted its quarterly earnings data on Tuesday, August 7th. The medical research company reported $0.24 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.17 by $0.07. The company had revenue of $29.66 million during the quarter, compared to analyst estimates of $30.19 million. Heska had a return on equity of 11.49% and a net margin of 4.67%. equities analysts expect that Heska Corp will post 1.67 EPS for the current fiscal year.
A number of research firms have recently commented on HSKA. Canaccord Genuity reaffirmed a “buy” rating and issued a $123.00 price target (up from $115.00) on shares of Heska in a report on Friday, June 15th. TheStreet lowered Heska from a “b” rating to a “c+” rating in a report on Monday, August 20th. ValuEngine lowered Heska from a “buy” rating to a “hold” rating in a report on Monday, July 30th. BidaskClub lowered Heska from a “strong-buy” rating to a “buy” rating in a report on Friday, July 27th. Finally, Benchmark began coverage on Heska in a report on Thursday, July 19th. They issued a “buy” rating and a $120.00 price target for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $107.50.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Recommended Story: Short Selling Stocks and Day Traders
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.